Open Access

The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors

Tomaz Smrkolj

Tomaz Smrkolj

  • Department of Urology, Ljubljana University Medical CentreLjubljana, Slovenia
  • Department of Surgery, Faculty of Medicine, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Smrkolj, Tomaz
, 
Urska Cegovnik Primozic

Urska Cegovnik Primozic

Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical CentreLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Cegovnik Primozic, Urska
, 
Teja Fabjan

Teja Fabjan

Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical CentreLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Fabjan, Teja
, 
Sasa Sterpin

Sasa Sterpin

Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical CentreLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Sterpin, Sasa
 and 
Josko Osredkar

Josko Osredkar

  • Clinical Institute of Clinical Chemistry and Biochemistry, Ljubljana University Medical CentreLjubljana, Slovenia
  • Faculty of Pharmacy, University of LjubljanaLjubljana, Slovenia
Search for this author on
Sciendo|Google Scholar
Osredkar, Josko
  
Dec 29, 2020
The performance of the Xpert Bladder Cancer Monitor Test and voided urinary cytology in the follow-up of urinary bladder tumors's Cover Image
About this article
Previous Article
Next Article
Cite
Download Cover
Article Category: Research Article
Published Online: Dec 29, 2020
Page range: 196 - 202
Received: Sep 22, 2020
Accepted: Nov 03, 2020
DOI: https://doi.org/10.2478/raon-2020-0072
Keywords
© 2021 Tomaz Smrkolj, Urska Cegovnik Primozic, Teja Fabjan, Sasa Sterpin, Josko Osredkar, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Figure 1

ROC curve for predicting cystoscopic finding.
ROC curve for predicting cystoscopic finding.

Figure 2

ROC curve for histology prediction.
ROC curve for histology prediction.

Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive cystoscopic findings

TestSensitivitySpecificityPPVNPV
XBC, LDATC 0.492375.0%95.2%81,8%93.0%
XBC, LDATC 0.566.7%95.2%80.0%90.9%
VUC41.7%97.6%83.3%85.4%
XBC, LDATC 0.4923 + VUC75.0%95.2%81,8%93.0%

Sensitivity of the XBC and voided urinary cytology stratified by tumour stage and grade_ Number of cases detected by noninvasive test against number of cases detected by hystology analysis is shown in the parenthsis

Test / StageCISTaT1T2GradePUNLMPlow gradehigh grade
XBC, LDATC 0.4923100%(2/2)80.0%(4/5)100%(2/2)100%(1/1)0.0%(0/1)66.7%(2/3)100.0%(7/7)
VUC50.0%(1/2)40.0%(2/5)50.0%(1/2)100%(1/1)0.0%(0/1)66.7%(2/3)42.9%(3/7)

Summary of the patients’ demographics and test results numbers

GenderNumber of patientsMean age, years ± SD
All54 (100.0%)70.5 ± 8.8
Male42 (77.8%)70.5 ± 8.7
Female12 (22.2%)70.5 ± 9.6
Noninvasive test / standard invasive diagnostic procedureNumber of patients with TP / FN / TN / FP noninvasive test result
XBC / cystocopy (LDATC 0.4923)9 / 3 / 40 / 2
XBC / cystocopy (LDATC 0.5)8 / 4 / 40 / 2
VUC / cystoscopy5 / 7 / 41 / 1
XBC / histology (LDATC 0.4923)10 / 3 / 40 / 1
XBC / histology (LDATC 0.5)9 / 4 / 40 / 1
VUC / histology5 / 8 / 40 / 1

Specificity, sensitivity and positive and negative predictive value of noninvasive urinary tests for the prediction of positive histological results

TestSensitivitySpecificityPPVNPV
XBC, LDATC 0.492376.9%97.5%90,9%93.0%
XBC, LDATC 0.569.2%97.5%90.0%90.9%
VUC38.4%97.5%83.3%83.3%
XBC, LDATC 0.4923 + VUC76.9%97.5%90,9%93.0%
Language:
English
Publication timeframe:
4 times per year
Journal Subjects:
Medicine, Clinical Medicine, Internal Medicine, Haematology, Oncology, Radiology
Journal RSS Feed